March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Cumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher rate of developing heart disease over five years, in an analysis from the D:A:D study.
No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry
The Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure.
On June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women.
Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results
Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...
Two small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ...
A reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain.
The leading U.S. HIV treatment guidelines developed by the U.S. Department of Health and Human Services (DHHS) for adults have several regimens that it recommends from which doctors and their patients can choose for the initial therapy of HIV. These ...
Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257
Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...